S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ALDX Aldeyra Therapeutics Inc

6.1799

0.1199 (1.98%)

After Hours

Last Updated: 08:30:16

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics Inc News

Form S-8 - Securities to be offered to employees in employee benefit plans
Saturday 1 March 2025 (4 days ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Saturday 1 March 2025 (4 days ago) • Edgar (US Regulatory)

Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Tuesday 4 February 2025 (4 weeks ago) • Business Wire

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
Monday 2 December 2024 (3 months ago) • Business Wire

Form 8-K - Current report
Monday 18 November 2024 (3 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
Monday 18 November 2024 (3 months ago) • Business Wire

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
Thursday 14 November 2024 (4 months ago) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 8 November 2024 (4 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
Thursday 31 October 2024 (4 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 22 October 2024 (4 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 3 October 2024 (5 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Thursday 3 October 2024 (5 months ago) • Business Wire

More Aldeyra Therapeutics Inc News Articles

Australian SE All Ordina...

Woodside Petroleum

Newcrest Mining

Commonwealth Bank Of Aus...

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions